BLOG

BioProcessOnline

Resilient Biopharma Leadership With Ambrx’s Dan O’Connor

Since Dan O’Connor stepped in as CEO at Ambrx late last year, the company’s stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O’Connor is no stranger to overcoming adversity.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}